Gocovri
Author: Daniel Chancellor
Publisher: Datamonitor Healthcare
- Description
- Companies
- Contents
- Enquire
Drug Overview
Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagonists on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Gocovri : Parkinson’s disease
LIST OF FIGURES
9 Figure 1: Gocovri for Parkinson’s disease – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Gocovri for Parkinson’s disease
13 Figure 4: Gocovri sales for Parkinson’s disease in the US, 2016–25
LIST OF TABLES
5 Table 1: Gocovri drug profile
7 Table 2: Gocovri pivotal trial data in Parkinson’s disease
13 Table 3: Gocovri sales for Parkinson’s disease in the US ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
ND0612 
Sign up to the